Not FDA Approved GH C-terminal Fragment Phase IIb Failed 2007

HGH Fragment
176–191

HGH Frag · GH Fragment · C-terminal Lipolytic Fragment

"The fat-burning fragment of growth hormone — isolated from the C-terminus of HGH specifically because it carries the lipolytic signal without the anabolic, IGF-1 raising, or glucose-disrupting effects. Promising in animals. A Phase IIb failure in humans. Still widely used."

Structure
16 AA · C-terminal fragment of HGH (residues 176–191)
FDA Status
Not approved · FDA Category 2
Key trial
Phase IIb 2007 — 536 patients — failed
Route
SubQ injection · typically 500mcg–2mg/day
WADA
Prohibited
Origin & Background

The lipolytic fragment of growth hormone

Human growth hormone has two biologically distinct domains: the N-terminal region responsible for growth promotion, IGF-1 stimulation, and anabolic effects; and the C-terminal region (amino acids 176–191) responsible for fat metabolism. HGH Fragment 176-191 was isolated by researchers who wanted the fat-burning properties of growth hormone without the growth, IGF-1, insulin resistance, and glucose disruption that comes with the full molecule.

The fragment activates β3-adrenergic receptors in adipocytes — stimulating lipolysis and inhibiting new fat storage — without binding the growth hormone receptor at all. This means no IGF-1 elevation, no insulin resistance, no glucose disruption, and no anabolic effects. In theory, a clean, targeted fat-loss signal.

Early Phase II human data was encouraging. A 2004 study showed 1mg/day produced approximately 3kg of fat loss over three months compared to placebo. Then came the Phase IIb trial in 2007: 536 participants, multiple dosing protocols, systematic failure to demonstrate clinical efficacy. The developer (Metabolic Pharmaceuticals) discontinued development. The fragment is now classified by the FDA as a Category 2 compound — meaning it cannot be legally compounded. Despite this, it remains one of the most widely used research peptides in the community.

HGH Frag 176-191 vs AOD-9604: AOD-9604 is a modified version of the same fragment with an additional tyrosine residue at the N-terminus. The two are closely related but technically distinct compounds. Both failed clinical development for the same reasons. AOD-9604 has a separate FDA Category 2 designation. The community often uses the names interchangeably, but they are different molecules.

Science & Mechanism

β3-adrenergic activation — without GH receptor binding

Mechanism of Action

1
No GH receptor binding: Unlike full HGH, Fragment 176-191 does not bind the growth hormone receptor. This eliminates IGF-1 stimulation, insulin resistance, glucose disruption, and anabolic effects. The fragment is entirely focused on adipose tissue metabolism.
2
β3-adrenergic receptor activation: Acts on β3-adrenergic receptors (ADRB3) in white and brown adipose tissue. ADRB3 activation increases intracellular cAMP, activates protein kinase A (PKA), and initiates lipolytic signalling cascades — breaking down stored triglycerides into free fatty acids.
3
Lipogenesis inhibition: Simultaneously inhibits the uptake of dietary fats into adipose cells — reducing new fat storage while increasing breakdown of existing fat stores.
4
Mitochondrial effects (2023 in vitro): A 2023 investigation using primary human adipocytes found the fragment increased uncoupling protein expression and mitochondrial oxygen consumption — suggesting fat oxidation capacity enhancement beyond simple lipolysis. This is the most recent mechanistic evidence.
5
Obesity-selective effect: Animal studies showed the fragment reduced fat in obese animals but had minimal effect in lean animals — suggesting the ADRB3 mechanism is more active under conditions of excess adiposity. This selectivity is mechanistically interesting but did not translate to human clinical efficacy.

The clinical failure requires honest explanation. The Phase IIb trial (536 participants, multiple dose arms) found no statistically significant advantage over placebo across any dosing protocol. The disconnect between animal success and human failure likely reflects the complexity of human energy balance — isolated lipolytic stimulation is insufficient to overcome compensatory mechanisms including appetite upregulation, metabolic adaptation, and behavioural factors. GH itself produces meaningful fat loss in humans through a more complex hormonal cascade; its isolated C-terminal fragment, operating through only one mechanism, appears insufficient.

Community Voices

What people report

Anecdotal ReportNot medical evidence · Individual experience

"Used it twice daily, 500mcg each, fasted, for 8 weeks alongside a deficit. Harder to attribute fat loss to the peptide vs the deficit. Body composition did shift — but I was also training hard and eating carefully. The peptide might have helped at the margins."

Male, 34. This attribution problem is central to HGH Frag community experience — it is almost always used alongside diet and training, making independent contribution difficult to assess. The modest 3kg advantage over placebo in the 2004 trial only emerged over 3 months in controlled conditions.

Anecdotal ReportNot medical evidence · Individual experience

"I stack it with CJC/Ipa for cutting phases. The idea is you're getting GH elevation from the secretagogues and targeted lipolysis from the fragment. I have no idea if the fragment is doing anything independently — the stack results are good but the stack has a lot of moving parts."

Female, 38, experienced peptide user. The HGH Frag + GH secretagogue stack is one of the most popular community cutting protocols. The logic is sound mechanistically — though disentangling each component's contribution is essentially impossible without controlled conditions.

Benefits & Evidence

What the data shows

🔥
Fat loss (animal models)
Consistent in obese rodent models — reduces fat mass, increases lipolysis, inhibits lipogenesis without affecting blood glucose or IGF-1. The mechanism is sound and well-characterised in preclinical settings.
● Moderate — strong animal data
👤
Fat loss (limited human data)
2004 early trial: ~3kg fat loss at 1mg/day over 3 months vs placebo. Phase IIb 2007 (n=536): failed to demonstrate clinical efficacy across multiple doses. The one positive signal did not replicate at scale.
● Limited — one positive, one failed Phase IIb
⚡
No IGF-1, no glucose disruption
The clean safety profile — no IGF-1 elevation, no insulin resistance, no glucose disruption — is genuinely distinctive. This makes it more tolerable than full GH for people concerned about those effects, even if the efficacy evidence is weak.
● Strong — well-established mechanistic characteristic
🦴
Cartilage regeneration (emerging)
A study combining HGH Frag 176-191 with hyaluronic acid showed greater cartilage formation in rabbit osteoporosis models than hyaluronic acid alone. An unexpected finding warranting further investigation.
● Emerging — single animal study
Safety First

Risks & considerations

⚠️
Better safety profile than full GH — but not approved and cannot be compounded. The absence of IGF-1 elevation and glucose effects makes this a cleaner compound than GH or most GH secretagogues. The main practical concern is FDA Category 2 status making legal access difficult and unregulated market quality uncertain.
Mild
Injection site reactions — transient redness and swelling. Common with SubQ administration.
Mild
Transient blood glucose effects — some animal data suggests mild transient insulin-like effects. Not confirmed to be clinically relevant in humans at standard doses.
Serious
FDA Category 2 — cannot be compounded: Unlike some other peptides, HGH Fragment 176-191 is FDA Category 2, meaning it cannot be legally prepared by compounding pharmacies in the US. It is only available through unregulated research chemical markets — meaning no quality control, no purity verification, and no dose accuracy assurance.
Unknown
Long-term effects unknown — clinical development was discontinued. No long-term safety data in humans exists. The animal safety profile is reassuring but limited.

⚠ Key Warnings

FDA Category 2 status means this compound cannot be legally compounded in the US. All available material is from unregulated sources — purity and dosing accuracy cannot be verified.
The Phase IIb trial failure is significant. Clinical development was discontinued for efficacy reasons, not safety. The community use continues despite the lack of demonstrated human efficacy at scale.
WADA prohibited at all times for competitive athletes.
Do not confuse with AOD-9604 — related but distinct compound with its own separate regulatory status.
Synergy Stack

Nutrients, Supplements & Exercise

HGH Fragment 176-191 works on adipose tissue lipolysis — the synergy stack focuses on creating the metabolic conditions where liberated fatty acids are actually burned as fuel, rather than recycled back into fat storage.

💊 Nutrients & Supplements
Fasted injection (essential)
Inject 30–60 min before fasted cardio or before bed
Strong evidence
The fragment stimulates lipolysis — releasing fatty acids into circulation. Insulin suppresses lipolysis directly. Always inject in a fasted state. Post-workout fasted or before bed are the most practical windows. Injecting post-carbohydrate meal largely negates the lipolytic effect.
T3/T4 (thyroid) — if clinically deficient
As prescribed by physician
Moderate evidence
β3-adrenergic signalling and thyroid hormones work synergistically on fat oxidation. Suboptimal thyroid function creates a ceiling on lipolytic signals. Check thyroid function before assuming peptide resistance — hypothyroidism explains many cases of poor fat loss response.
CJC-1295 / Ipamorelin combination
Standard GH secretagogue stack alongside
Moderate evidence
The community rationale: GH secretagogues raise GH broadly (anabolic + lipolytic); HGH Frag adds a targeted lipolytic signal without the systemic GH effects. Whether the fragment adds meaningfully on top of the secretagogue stack is unproven — but the combination is one of the most popular cutting protocols.
Caffeine / green tea extract
200–400mg caffeine or 400mg EGCG pre-cardio
Moderate evidence
Caffeine directly enhances β-adrenergic signalling and fat oxidation — working through the same adrenergic family of receptors as HGH Frag's β3 mechanism. The combination amplifies lipolytic signalling and ensures the released fatty acids are oxidised during exercise rather than recycled.
🏃 Exercise & Lifestyle
Fasted cardio immediately post-injection
The most evidence-rationale-supported application: inject HGH Frag 30–60 minutes before fasted low-to-moderate intensity cardio. The fragment stimulates lipolysis; aerobic exercise creates the energy demand to oxidise the released fatty acids. Without the exercise stimulus, liberated fat may simply recirculate rather than be burned.
Caloric deficit (required)
The Phase IIb failure likely reflects that isolated lipolysis stimulation is insufficient without a caloric deficit. The fragment is not a substitute for energy balance — it is, at best, a marginal amplifier of a deficit that must already exist. Anyone not in a caloric deficit should address that first.
Resistance training to preserve muscle
Unlike GH or IGF-1, HGH Fragment has no anabolic properties — it will not preserve muscle during a deficit. Resistance training is essential for lean mass maintenance. The fragment addresses only one side of body recomposition.
⏱ Timing & Protocol Notes
Typical community protocol: 500mcg–1mg SubQ, twice daily, fasted. First dose before morning fasted cardio; second dose before bed. Always fasted — never post-meal. Cycle 8–12 weeks. The twice-daily protocol attempts to maintain more sustained lipolytic pressure than the 2004 trial's once-daily protocol.

Disclaimer: HGH Fragment 176-191 is not FDA approved, is FDA Category 2 (cannot be compounded), and has failed Phase IIb human clinical trials. Use is research-only. The Phase IIb failure should be taken seriously — community reports of efficacy likely reflect the underlying caloric deficit and training, not the peptide's independent contribution.

Honest Assessment

Editor's summary

HGH Fragment 176-191 is one of the most popular research peptides in the fat-loss community — and one of the most honestly complicated to assess. The mechanism is sound, the animal data is consistent, the safety profile is genuinely better than full GH, and the 2004 early human trial was promising. The 2007 Phase IIb failure across 536 participants across multiple doses is real and cannot be dismissed.

The community continues using it because isolated lipolysis stimulation makes mechanistic sense, the safety profile is clean, and the compound is cheap relative to GH secretagogues. Whether it adds meaningfully to a well-designed cutting protocol with diet and training is genuinely unknown — the clinical failure tells us it doesn't work as a standalone intervention in free-living subjects, not that it contributes nothing as part of a comprehensive stack.

The FDA Category 2 designation adds a significant practical barrier — all available material is from unregulated sources, meaning purity and dose accuracy are unverifiable. This is a meaningful safety concern that the community routinely underweights.

Verdict
"Clean mechanism, good safety profile, failed Phase IIb. The honest verdict: probably not doing much as a standalone intervention; possibly contributing something at the margins of a comprehensive cutting stack. The FDA Category 2 status and unregulated sourcing are the most important practical concerns."